Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Urinary Bladder Neoplasms × durvalumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Small Cell Lung Carcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Ovarian Neoplasms 1 Non Small Cell Lung Cancer NSCLC 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1

Interventions

enfortumab vedotin 3 Gemcitabine 2 Cisplatin 2 vinflunine 1 sacituzumab govitecan 1 pembrolizumab 1 durvalumab 1 avelumab 1 Paclitaxel 1 Mitomycin 1 Docetaxel 1 Carboplatin 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03732677 2026-03-13

NIAGARA

AstraZeneca

Phase 3 Active not recruiting

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡